Spyre Therapeutics CLO Heidy King-Jones Sells $2.6M Stock

Spyre Therapeutics Chief Legal Officer and Corporate Secretary Heidy King-Jones sold $2.6 million in common stock under a pre-arranged trading plan, while concurrently exercising stock options to acquire additional shares.

The transaction details emerge as Spyre Therapeutics shares trade at $83.21, marking a 4.14% increase from its previous close of $79.90, according to Finnhub market data as of October 9, 2026.

Breakdown of the Insider Transactions

On October 1, 2026, Ms. King-Jones executed the sale of 28,933 shares of common stock, totaling approximately $2,633,901, according to an Investing.com report. The shares were sold at prices ranging between $89.24 and $93.46 per share.

The transactions were carried out pursuant to a Rule 10b5-1 trading plan that was adopted earlier in the year on April 16, 2026. Concurrently, Ms. King-Jones acquired 28,933 shares through the exercise of stock options at a price of $14.50 per share, amounting to a total valuation of approximately $419,528.

Understanding Rule 10b5-1 Trading Plans

Corporate insiders frequently utilize Rule 10b5-1 plans to buy or sell company stock without running afoul of insider trading regulations. These mechanisms allow executives to establish a predetermined schedule for executing trades at a future date when they are not in possession of material non-public information.

By setting the parameters in advance, including specific dates, pricing thresholds, or share quantities, insiders insulate themselves from potential accusations of trading on short-term market fluctuations or confidential corporate developments.